G-CSF Combined With IL-11 on Hematopoietic Reconstitution After Autologous Hematopoietic Stem Cell Transplantation
Recruiting
Phase 2
Interventional Study
Mobilization of Hematopoietic Stem Cells (HSC) to Peripheral Blood (PB)
Hematopoetic Stem Cell Transplantation
Hemato-oncologic Patients
No Placebo Group
Every participant receives an active treatment — no one gets a placebo.
Prior Safety Data
This treatment has already been tested in at least one earlier human trial.
At a Glance
- Age
- 18 – 70
- Sex
- Any
- Trial phase
- Phase 2
- Study type
- Interventional
- Purpose
- Treatment
- Participants needed
- 224 (estimated)
- Sponsor
- Fudan University · Other
Think this trial could be right for you?
Answer a few quick questions to see if you may meet the eligibility requirements.
Check Your Eligibility
About This Trial
Autologous hematopoietic stem cell transplantation(auto-HSCT) plays an important role in treating hematologic malignancies. Mobilization and collection of peripheral blood stem/progenitor cells is the key to successful autologous hematopoietic stem cell transplantation. Currently mobilization regimens are not enough in increasing the yield of megakaryocytic or erythroid stem/progenitor cells, resu…
Trial Locations
Loading…
Loading trial locations…
Eligibility Criteria
Inclusion Criteria:
* Adults (≥18 years) with newly diagnosed multiple myeloma or lymphoma
* Suitable candidates for autologous hematopoietic stem cell transplantation (auto-HSCT)
* Zubrod (ECOG) performance status \< 4
* Left ventricular ejection fraction (LVEF) \> 40%
* No uncontrolled arrhythmia…
Contacts